EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults

Craig M Comisar, Jim H Hughes iD, Jose Francis iD, Yorinao Chinda iD, Yamato Sano iD, Chieko Muto iD, Christine Neumar iD, Rajinder Bhardwaj, Richard Bertz iD, Jing Liu iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Craig M Comisar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Certara USA, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Models, Biological, Piperidines, Pyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biohaven Pharmaceuticals Inc, Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rimegepant is a small‐molecule calcitonin gene‐related peptide receptor antagonist approved for acute and preventive migraine treatment in adults, administered as an orally disintegrating tablet (ODT). A population pharmacokinetic analysis was performed to describe rimegepant's plasma concentration‐time course and to estimate covariate effects on rimegepant exposure. The model was developed/evaluated in 3 stages using data from 11 phase 1 clinical studies, wherein rimegepant was administered orally to healthy adults, elderly people with stable chronic illness(es), adults with renal or hepatic dysfunction, and healthy adults with Japanese or Chinese ethnicity. Plasma concentration‐time data were analyzed using nonlinear mixed effects modeling. A 2‐compartment model with 4 transit compartments and a first‐order absorption best described the rimegepant plasma concentration‐time course. Estimated typical values (%relative standard error) were apparent clearance (CL/F) = 24.1 L/h (4.86%), apparent central volume of distribution (V c /F) = 114.0 L (5.36%), apparent inter‐compartmental clearance (Q/F) = 3.94 L/h (6.37%), apparent peripheral volume of distribution (V p /F) = 46.0 L (5.30%), absorption rate constant ( k a ) = 3.86 h −1 (28.4%), and transit absorption rate constant (ktr) = 8.23 h −1 (8.24%). Statistically significant covariates included empirical allometric body weight‐based scaling exponents (0.75 for CL/F and Q/F and 1 for V c /F and V p /F); severe/moderate hepatic impairment and fluconazole/itraconazole co‐administration on CL/F; fed status, dose on relative bioavailability; and fed status, itraconazole co‐administration, and capsule and ODT formulations on transition absorption rate constant. Only severe hepatic impairment and co‐administration of itraconazole resulted in a clinically significant decrease in rimegepant CL/F, supporting the recommendation to avoid rimegepant administration in patients with severe hepatic impairment or with a strong CYP3A4 inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsModels, BiologicalPiperidinesPyridinesAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralClinical Trials, Phase I as Topic

Stichwörter der Autor:innen

calcitonin gene‐related peptide receptor antagonistsmigrainepopulation pharmacokinetic modelingrimegepant

Substanzen

Calcitonin Gene-Related Peptide Receptor AntagonistsPiperidinesPyridinesrimegepant sulfate

Autor:innen und Institutionen

  • Certara USA, Princeton, New Jersey, USA.
  • Pfizer Inc, New York, New York, USA.
  • Pfizer Inc Japan, Tokyo, Japan.
  • Biohaven Pharmaceuticals Inc, New Haven, Connecticut, USA.

ORCID-Profile: Jim H Hughes, Jose Francis, Yorinao Chinda, Yamato Sano, Chieko Muto, Christine Neumar, Richard Bertz, Jing Liu

Förderung

  • Biohaven Pharmaceuticals Inc
  • Pfizer Inc

Zitieren

APA

Comisar, C. M., Hughes, J. H., Francis, J., Chinda, Y., Sano, Y., Muto, C., Neumar, C., Bhardwaj, R., Bertz, R., & Liu, J. (2025). Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70051

Vancouver

Comisar CM, Hughes JH, Francis J, Chinda Y, Sano Y, Muto C, et al. Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70051

BibTeX
@article{Comisar2025,
  author = {Comisar, Craig M and Hughes, Jim H and Francis, Jose and Chinda, Yorinao and Sano, Yamato and Muto, Chieko and Neumar, Christine and Bhardwaj, Rajinder and Bertz, Richard and Liu, Jing},
  title = {Population Pharmacokinetic Modeling of the Oral Calcitonin Gene‐Related Peptide Receptor Antagonist Rimegepant in Adults},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70051}
}
Kostenlos starten →